
IFPA
GLOBAL LEADER IN FIGHTING PSORIATIC DISEASE

ECONOMIC BENEFITS OF EARLY TREATMENT FOR PSORIATIC DISEASE

How early intervention can reduce the burden of related comorbidities and save billions

Psoriatic disease is a systemic condition affecting multiple body sites, predominately the skin, the joints, or both. A third of people with skin manifestations of psoriatic disease (psoriasis) will develop a type of inflammatory arthritis affecting joints and tendons (psoriatic arthritis)[1].

People with psoriatic disease have an increased risk of developing other serious diseases, called **comorbidities**, such as:



Cardiovascular disease | **Obesity** | **Diabetes** | **Depression**

Treatment of these comorbidities is a cost for healthcare systems and for societies[2].

Does treating psoriatic disease reduce the costs of treating its comorbidities?



Denmark | **USA** | **Vietnam**

Data retrieved from scientific literature were input in an economic model to calculate direct (healthcare) and indirect (societal) comorbidity cost savings[3].

HEALTHCARE AND SOCIETAL COSTS FOR TREATING COMORBIDITIES ARE REDUCED WITH TIMELY AND EFFECTIVE TREATMENT OF PSORIATIC DISEASE

Healthcare costs for treating comorbidities are reduced with timely and effective treatment of psoriatic disease



Effective treatment reduces costs by **35.5%** compared with untreated or undertreated psoriatic disease.

Societal costs for treating comorbidities are reduced with timely and effective treatment of psoriatic disease



Effective treatment reduces costs by **32.5%** compared with untreated or undertreated psoriatic disease.

Cost offset for all comorbidities, from all three countries

Conclusion

Timely and efficacious treatment of psoriatic disease reduces the economic burden of comorbidities, for both healthcare systems and societies.

Act now!

People living with psoriatic disease should have access to timely and efficacious treatment:

- The physical and psychosocial impact of the disease are alleviated
- The financial burden on health systems due to the development of comorbidities is reduced
- The costs for societies and individuals decrease

References:
1. IFPA | our cause ifpa-pso.com/about-ifpa/our-cause
2. IFPA | psoriatic disease and comorbidities ifpa-pso.com/resources-tools/psoriatic-disease-comorbidities
3. Norton, Nicholas et al. “Economic Impact of Timely Systemic Treatment of Psoriatic Disease in Comorbidity Risk Reduction: Literature Review and (Early) Economic Assessment.” Dermatology and therapy vol. 16,7 (2026): 3687-3707. doi:10.1007/s13555-026-01814-x